Business
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
BOSTON & DAEJEON, South Korea, November 03, 2025--Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
About this update from Orum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":228,"url":"https://media.zenfs.com/en/business-wire.com/7908b457e2cb4e8d56838d6e182f482e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IMUAbr3noUTW9eZxYxw7IQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ1NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7908b457e2cb4e8d56838d6e182f482e","width":480,"height":228}},"lazy":false},{"type":"text","content":"BOSTON & DAEJEON, South Korea, November 03, 2025--(BUSINESS WIRE)--Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that preclinical data for ORM-1153, a CD123-targeting DAC with a GSPT1-degrading payload, have been selected for presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6 to 9, 2025, in Orlando, Florida.","length":514,"tagName":"p"},{"type":"text","content":"The presentation will feature data from preclinical studies of ORM-1153, a novel CD123-targeting DAC designed to deliver Orum’s proprietary GSPT1-degrading payload, SMol006, selectively into cancer cells to achieve targeted protein degradation and antitumor activity in acute myeloid leukemia (AML). The results support further investigation of ORM-1153 as a potential therapeutic option for AML and other CD123-positive hematologic malignancies, including those with TP53-mutant status.","length":487,"tagName":"p"},{"type":"text","content":"Details of the ASH 2025 Presentation","length":36,"tagName":"p"},{"type":"text","content":"Title: ORM-1153: A CD123-Targeting Degrader Antibody Conjugate with GSPT1-Degrading Payload Exhibits Potent Preclinical Antitumor Activity in Acute Myeloid LeukemiaSession: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster IIISession Type: Poster PresentationSession Date and Time: December 8, 2025, from 6 pm to 8 pm ETLocation: Orange County Convention Center (OCCC), West Halls B3-B4Abstract Number: 5051","length":437,"tagName":"p"},{"type":"text","content":"About Orum’s TPD²® Approach","length":27,"tagName":"p"},{"type":"text","content":"Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel ta...